» Articles » PMID: 36009075

Elevated Hexose-6-Phosphate Dehydrogenase Regulated by OSMR-AS1/hsa-miR-516b-5p Axis Correlates with Poor Prognosis and Dendritic Cells Infiltration of Glioblastoma

Overview
Journal Brain Sci
Publisher MDPI
Date 2022 Aug 26
PMID 36009075
Authors
Affiliations
Soon will be listed here.
Abstract

Objective Glioblastoma (GBM), a type of malignant glioma, is the most aggressive type of brain tumor and is associated with high mortality. Hexose-6-phosphate dehydrogenase (H6PD) has been detected in multiple tumors and is involved in tumor initiation and progression. However, the specific role and mechanism of H6PD in GBM remain unclear. Methods We performed pan-cancer analysis of expression and prognosis of H6PD in GBM using the Genotype-Tissue Expression Project (GTEx) and The Cancer Genome Atlas (TCGA). Subsequently, noncoding RNAs regulating H6PD expression were obtained by comprehensive analysis, including gene expression, prognosis, correlation, and immune infiltration. Finally, tumor immune infiltrates related to H6PD and survival were performed. Results Higher expression of H6PD was statistically significantly associated with an unfavorable outcome in GBM. Downregulation of hsa-miR-124-3p and hsa-miR-516b-5p in GBM was detected from GSE90603. Subsequently, OSMR-AS1 was observed in the regulation of H6PD via hsa-miR-516b-5p. Moreover, higher H6PD expression significantly correlated with immune infiltration of dendritic cells, immune checkpoint expression, and biomarkers of dendritic cells. Conclusions The OSMR-AS1/ miR-516b-5p axis was identified as the highest-potential upstream ncRNA-related pathway of H6PD in GBM. Furthermore, the present findings demonstrated that H6PD blockading might possess antitumor roles via regulating dendritic cell infiltration and immune checkpoint expression.

Citing Articles

Profiling hypoxia signaling reveals a lncRNA signature contributing to immunosuppression in high-grade glioma.

Li X, Xu J, Li X, Shi J, Wei C, Liang Q Front Immunol. 2024; 15:1471388.

PMID: 39416790 PMC: 11479907. DOI: 10.3389/fimmu.2024.1471388.


Predictive Model to Identify the Long Time Survivor in Patients with Glioblastoma: A Cohort Study Integrating Machine Learning Algorithms.

Yang X, Zeng Z, Wang C, Sheng Y, Wang G, Zhang F J Mol Neurosci. 2024; 74(2):48.

PMID: 38662286 DOI: 10.1007/s12031-024-02218-2.

References
1.
Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D . MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun. 2015; 6:8755. PMC: 4659938. DOI: 10.1038/ncomms9755. View

2.
Petitprez F, Meylan M, De Reynies A, Sautes-Fridman C, Fridman W . The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Front Immunol. 2020; 11:784. PMC: 7221158. DOI: 10.3389/fimmu.2020.00784. View

3.
Puduvalli V, Yung W, Hess K, Kuhn J, Groves M, Levin V . Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004; 22(21):4282-9. PMC: 3820102. DOI: 10.1200/JCO.2004.09.096. View

4.
Tsachaki M, Mladenovic N, Stambergova H, Birk J, Odermatt A . Hexose-6-phosphate dehydrogenase controls cancer cell proliferation and migration through pleiotropic effects on the unfolded-protein response, calcium homeostasis, and redox balance. FASEB J. 2018; 32(5):2690-2705. PMC: 5901385. DOI: 10.1096/fj.201700870RR. View

5.
Xu X, Wang L, Zang Q, Li S, Li L, Wang Z . Rewiring of purine metabolism in response to acidosis stress in glioma stem cells. Cell Death Dis. 2021; 12(3):277. PMC: 7961141. DOI: 10.1038/s41419-021-03543-9. View